CANCER IS OUR CAUSE
U.S. FDA approves new indication
Our flagship medicine is now available for certain patients with previously treated advanced neuroendocrine tumors.
Read Our Press Release
Because every day counts
Our success as a business is intrinsically tied to our ability to do more for patients.
Explore our 2024 Annual Report
Our environmental, social and governance initiatives
Learn more about these themes and progress in our Corporate Values & Sustainability Report.
Read Our 2024 Report
Patent litigation announcement
Read an update on the favorable ruling from the patent litigation involving our flagship therapy.
See Our Press Release
Advancing our pipeline
Learn about our first pivotal trial in squamous cell carcinoma of the head and neck.
Read Our News
An exceptional employee experience
Experience more purposeful work and fulfilling opportunities.
See Open Jobs
Accelerating our impact in oncology
Develop next-generation cancer medicines with us.
Let’s Collaborate
Supporting our community
We are champions for causes we believe in.
See Our Impact
Inspired by science
Leveraging deep expertise in chemistry and biology, as well as strategic partnerships, we are advancing various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, antibody-drug conjugates and other innovative treatments.
Our discovery teams are advancing multiple small molecule programs internally and through our industry collaborations.
Our R&D programs include next-generation approaches to established targets, as well as opportunities to be first-in-class by applying a range of modalities and mechanisms of action across biologics and small molecules.
